STOCK TITAN

Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.

About Ginkgo Bioworks Holdings Inc. (NYSE: DNA)

Ginkgo Bioworks Holdings Inc. is a pioneering company in the field of synthetic biology, operating a horizontal platform for cell programming that provides end-to-end solutions across diverse industries. Headquartered in Boston, Massachusetts, Ginkgo leverages its cutting-edge technologies to design, build, and test engineered organisms, addressing challenges in sectors such as pharmaceuticals, agriculture, industrial and specialty chemicals, and biosecurity.

Core Business Areas

Cell Engineering: The Cell Engineering segment is the cornerstone of Ginkgo's operations. Utilizing its proprietary Foundry platform, the company offers biological research and development services to customers. This includes engineering cells to produce specific molecules, optimize industrial processes, or develop new products. The Foundry integrates automation, high-throughput screening, and machine learning to streamline the design-build-test cycle, enabling scalable and cost-effective solutions.

Biosecurity: Ginkgo's Biosecurity segment provides critical services to government and commercial entities to identify, monitor, and mitigate biological threats. This includes solutions for pandemic preparedness, pathogen detection, and biosurveillance. By combining its expertise in synthetic biology with advanced diagnostics, Ginkgo supports public health and global biosecurity initiatives.

Platform Capabilities

Ginkgo's platform is underpinned by its extensive Codebase, a repository of biological data and engineered organisms, and its Foundry, which automates and accelerates the engineering of biological systems. The company's integration of artificial intelligence and machine learning enhances its ability to design complex biological systems, such as protein language models and genomic tools, further distinguishing its capabilities.

Industry Applications

  • Pharmaceuticals: Ginkgo collaborates with biotech and pharmaceutical companies to accelerate drug discovery, optimize biologic manufacturing, and develop advanced therapies, including cell and gene therapies.
  • Agriculture: The company partners with agricultural innovators to create sustainable solutions, such as bioengineered feed additives and crop protection products.
  • Industrial Chemicals: Ginkgo designs microorganisms that produce specialty chemicals, enabling more sustainable and cost-effective manufacturing processes.
  • Biosecurity: Through initiatives like pathogen detection and rapid diagnostics, Ginkgo plays a vital role in strengthening global health resilience.

Competitive Positioning

Ginkgo Bioworks differentiates itself through its horizontal platform model, which allows it to serve a wide range of industries with scalable and customizable solutions. Unlike vertically integrated competitors, Ginkgo's platform approach enables it to collaborate broadly, leveraging its expertise in synthetic biology to meet diverse customer needs. Its partnerships with entities like Google Cloud and global pharmaceutical leaders highlight its strategic positioning and technical capabilities.

Challenges and Opportunities

Operating in a highly regulated and competitive industry, Ginkgo faces challenges such as customer adoption, regulatory compliance, and market volatility. However, its focus on innovation, such as the development of AI-driven tools and biosecurity solutions, positions it to capitalize on emerging opportunities in synthetic biology and global health.

Conclusion

Ginkgo Bioworks Holdings Inc. stands at the forefront of synthetic biology, offering a unique platform that combines advanced engineering, automation, and biosecurity capabilities. By addressing complex challenges across multiple industries, Ginkgo continues to redefine the possibilities of biotechnology, making biology easier to engineer and more impactful for its partners and stakeholders.

Rhea-AI Summary
ProteoNic Biosciences partners with Ginkgo Bioworks (NYSE: DNA) to provide premium vector technology for biologics production, expanding into cell and gene therapy applications. This collaboration aims to drive innovation, enhance production capabilities, and reduce manufacturing costs in the biotech industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
Ginkgo Bioworks Holdings, Inc. (DNA) reported $251 million in total revenue for 2023, with $139 million in Cell Engineering services revenue, representing 31% growth over 2022. The company added 78 new Cell Programs in 2023, showing 32% growth over the previous year. Ginkgo's year-end cash balance of nearly $950 million provides a strong financial runway. The company is focused on biopharma growth, global biosecurity, and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.13%
Tags
-
Rhea-AI Summary
bit.bio, a company coding human cells for novel cures, partners with Ginkgo Bioworks (NYSE: DNA) to integrate its ioCells™ portfolio of precision reprogrammed human cells into Ginkgo's platform ecosystem. This collaboration aims to provide physiologically-relevant human cell models at scale for Ginkgo's biopharma clients, enhancing disease biology insights and accelerating preclinical research and drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced grants of restricted stock units worth $4,292,000 to Patch Bio employees and $3,530,000 to Reverie Labs employees. The units were approved as inducements for employment, vesting over time based on continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Ginkgo Bioworks (DNA) acquires key assets of Reverie Labs to enhance AI-driven drug discovery efforts. The acquisition includes infrastructure, software, and key team members to strengthen Ginkgo's AI/ML capabilities. The move aims to accelerate the development of next-generation biological foundation models and advance AI/ML-driven experimental design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Ginkgo Bioworks (DNA) acquires Proof Diagnostics, a life sciences company specializing in genome engineering tools for therapeutic and diagnostic applications. The acquisition aims to enhance Ginkgo's Gene Therapy Services and advance precision gene editing capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) acquires Patch Biosciences to enhance its gene therapy, cell therapy, and RNA therapeutics services. The acquisition aims to integrate Patch's AI platform for sequence design into Ginkgo's existing platform, offering new capabilities in genetic medicine. Ginkgo's collaborations with Pfizer and Sensible Biotechnologies, along with a successful manufacturing optimization program with Biogen, highlight the company's commitment to innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Ginkgo Bioworks (DNA) announces the creation of the Ginkgo Technology Network, a collaborative ecosystem of technology partners aimed at enhancing R&D outcomes in biological end markets. By integrating AI, genetic medicines, biologics, and manufacturing capabilities, Ginkgo plans to provide customers with comprehensive solutions. The network aims to eliminate siloing and switching costs, with plans to expand by adding new partners over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks partners with Qatar Free Zones Authority and Doha Venture Capital to establish the Center for Unified Biosecurity Excellence (CUBE-D) in Doha, a cutting-edge hub for global pathogen monitoring and biosecurity efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.29%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced CEO Jason Kelly's participation in Cowen's 44th Annual Health Care Conference. Details available on Ginkgo's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.29%
Tags
none

FAQ

What is the current stock price of Ginkgo Bioworks Holdings (DNA)?

The current stock price of Ginkgo Bioworks Holdings (DNA) is $8.01 as of March 3, 2025.

What is the market cap of Ginkgo Bioworks Holdings (DNA)?

The market cap of Ginkgo Bioworks Holdings (DNA) is approximately 468.3M.

What does Ginkgo Bioworks do?

Ginkgo Bioworks operates a horizontal platform for cell programming, providing end-to-end solutions for industries like pharmaceuticals, agriculture, and biosecurity.

How does Ginkgo Bioworks generate revenue?

The company generates revenue primarily through its Cell Engineering segment by offering biological R&D services and its Biosecurity segment by providing pathogen detection and mitigation solutions.

What industries does Ginkgo Bioworks serve?

Ginkgo serves industries including pharmaceuticals, agriculture, industrial and specialty chemicals, and biosecurity.

What makes Ginkgo Bioworks unique?

Ginkgo's horizontal platform model, which combines synthetic biology, automation, and AI, allows it to scale solutions across diverse industries, differentiating it from vertically integrated competitors.

What is Ginkgo's Foundry platform?

The Foundry is Ginkgo's proprietary platform that integrates automation, high-throughput screening, and machine learning to design, build, and test engineered organisms efficiently.

What is the role of AI in Ginkgo's operations?

Ginkgo uses AI and machine learning to enhance its synthetic biology capabilities, including protein language models and genomic tools, enabling faster and more precise biological engineering.

What are the challenges Ginkgo Bioworks faces?

Key challenges include regulatory compliance, customer adoption of its platform, market competition, and the complexity of scaling synthetic biology solutions.

Who are Ginkgo's competitors?

Competitors include other synthetic biology companies like Zymergen and Amyris, though Ginkgo's horizontal platform approach sets it apart.

What is Ginkgo's role in biosecurity?

Ginkgo provides biosecurity solutions, including pathogen detection, pandemic preparedness, and biosurveillance, to enhance global health resilience.

How does Ginkgo collaborate with other companies?

Ginkgo partners with organizations across industries, leveraging its platform to co-develop solutions, such as drug discovery tools with pharmaceutical companies and sustainable products in agriculture.
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

468.33M
54.25M
6.68%
67.62%
13.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON